These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 19567350)

  • 1. Intravenous amoxicillin-sulbactam against Escherichia coli: optimizing the dose, component ratio and infusion time using a human pharmacodynamic model.
    Bantar C; Fernandez Canigia L; Berger MA; Soutric JL; Arenoso HJ
    J Chemother; 2009 Jun; 21(3):296-301. PubMed ID: 19567350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic assessment of Amoxicillin-Sulbactam against Acinetobacter baumannii: searching the optimal dose and infusion time through a human ex-vivo model.
    Bantar C; Canigia LF; Berger MA; Soutric JL; Arenoso HJ
    Braz J Infect Dis; 2009 Oct; 13(5):348-52. PubMed ID: 20428633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pharmacodynamic model to support a 12-hour dosing interval for amoxicillin/sulbactam, a novel oral combination, in the treatment of community-acquired lower respiratory tract infections.
    Bantar C; Nicola F; Fernandez Canigia L; Arenoso HJ; Soutric J; Montoto M; Blanco M; Smayevsky J; Jasovich A
    J Chemother; 2000 Jun; 12(3):223-7. PubMed ID: 10877517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An ex-vivo pharmacodynamic study comparing bactericidal activity of amoxicillin/sulbactam, azithromycin, doxycycline and levofloxacin against Streptococcus pneumoniae.
    Bantar C; Nicola F; Arenoso H; Soutric J; Caruso N; Fernández Canigia L
    J Chemother; 2004 Jun; 16(3):248-54. PubMed ID: 15330320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale for treating community-acquired lower respiratory tract infections with amoxicillin/sulbactam combination through pharmacodynamic analysis in the setting of aminopenicillin-resistant organisms.
    Bantar C; Nicola F; Fernandez Canigia L; Arenoso HJ; Soutric J; Montoto M; Blanco M; Smayevsky J; Jasovich A
    J Chemother; 2001 Aug; 13(4):402-6. PubMed ID: 11589483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of amoxicillin-sulbactam, a novel aminopenicillin-beta-lactamase inhibitor combination, against Escherichia coli.
    Bantar C; Nicola F; Arenoso HJ; Galas M; Soria L; Dana D; Rossi A; Bianchini H; Jasovich A
    Antimicrob Agents Chemother; 1999 Jun; 43(6):1503-4. PubMed ID: 10348782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary concentrations and bactericidal activity against amoxicillin-nonsusceptible strains of Escherichia coli with single-dose, oral, sustained-release amoxicillin/clavulanic acid: a phase I, open-label, noncomparative clinical trial in healthy volunteers.
    Ponte C; Gracia M; Giménez MJ; Aguilar L; Maín CM; Carpintero Y; Huelves L; Carcas A; del Prado G; Soriano F
    Clin Ther; 2005 Jul; 27(7):1043-9. PubMed ID: 16154483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urine inhibitory titers against resistant Escherichia coli isolates after oral amoxicillin-sulbactam.
    Casellas JM; Visser M; MacDougall N; Tomé G; Cohen HS; Soutric J; Arenoso H;
    Medicina (B Aires); 2003; 63(3):211-4. PubMed ID: 12876904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the pharmacodynamic activity of cefotaxime plus metronidazole with cefoxitin and ampicillin plus sulbactam.
    Sullivan MC; Nightingale CH; Quintiliani R; Sweeney KR
    Pharmacotherapy; 1995; 15(4):479-86. PubMed ID: 7479201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Escherichia coli eradication from the blader urine by amoxicillin-sulbactam. Intrinsic activity of the inhibitor].
    Casellas JM; Visser M; Tomé G; Cohen H; Soutric J; Arenoso H
    Enferm Infecc Microbiol Clin; 2001 May; 19(5):206-10. PubMed ID: 11446908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics of ampicillin-sulbactam in an in vitro infection model against Escherichia coli strains with various levels of resistance.
    Lamp KC; Vickers MK
    Antimicrob Agents Chemother; 1998 Feb; 42(2):231-5. PubMed ID: 9527765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ex vivo pharmacodynamics of amoxicillin-clavulanate against beta-lactamase-producing Escherichia coli in a yucatan miniature pig model that mimics human pharmacokinetics.
    Bronner S; Murbach V; Peter JD; Levêque D; Elkhaïli H; Salmon Y; Dhoyen N; Monteil H; Woodnutt G; Jehl F
    Antimicrob Agents Chemother; 2002 Dec; 46(12):3782-9. PubMed ID: 12435677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the pharmacokinetics of piperacillin and sulbactam during intermittent and continuous intravenous infusion.
    Langgartner J; Lehn N; Glück T; Herzig H; Kees F
    Chemotherapy; 2007; 53(5):370-7. PubMed ID: 17785973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of amoxicillin-sulbactam, given twice-a-day, for the treatment of community-acquired pneumonia: a clinical trial based on a pharmacodynamic model.
    Jasovich A; Soutric J; Morera G; Mastruzzo M; Vesco E; Izaguirre M; Mobilia L; Prieto S; Franco D; Curcio D; Absi R; Larrateguy L; Bustos JL; Oliva ME; Arenoso H; Bantar C
    J Chemother; 2002 Dec; 14(6):591-6. PubMed ID: 12583551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of ampicillin-sulbactam and ticarcillin-clavulanic acid in patients with chronic renal failure: effects of differential pharmacokinetics on serum bactericidal activity.
    Hardin TC; Butler SC; Ross S; Wakeford JH; Jorgensen JH
    Pharmacotherapy; 1994; 14(2):147-52. PubMed ID: 8197032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial effects of varied combinations of meropenem, sulbactam, and colistin on a multidrug-resistant Acinetobacter baumannii isolate that caused meningitis and bacteremia.
    Lee CH; Tang YF; Su LH; Chien CC; Liu JW
    Microb Drug Resist; 2008 Sep; 14(3):233-7. PubMed ID: 18707240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients.
    Cheatham SC; Shea KM; Healy DP; Humphrey ML; Fleming MR; Wack MF; Smith DW; Sowinski KM; Kays MB
    Int J Antimicrob Agents; 2011 Jan; 37(1):46-50. PubMed ID: 21074370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulsatile delivery of amoxicillin against Streptococcus pneumoniae.
    Cha R; Rybak MJ
    J Antimicrob Chemother; 2004 Dec; 54(6):1067-71. PubMed ID: 15486084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic activity of ertapenem versus genotypically characterized extended-spectrum β-lactamase (ESBL)-, KPC- or NDM-producing Escherichia coli with reduced susceptibility or resistance to ertapenem using an in vitro model.
    Zhanel GG; Denisuik A; Vashisht S; Yachison C; Adam HJ; Hoban DJ
    J Antimicrob Chemother; 2014 Sep; 69(9):2448-52. PubMed ID: 24827891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.